Abstract: Disclosed is a transformed yeast cell containing a first heterologous DNA sequence which codes for a mammalian G protein-coupled receptor and a second heterologous DNA sequence which codes for a mammalian G protein ? subunit (mammalian G?). The first and second heterologous DNA sequences are capable of expression in the cell, but the cell is incapable of expressing an endogenous G protein ?-subunit (yeast G?). The cells are useful for screening compounds which affect the rate of dissociation of G? from G?? in a cell. Also disclosed is a novel DNA expression vector useful for making cells as described above. The vector contains a first segment comprising at least a fragment of the extreme amino-terminal coding sequence of a yeast G protein-coupled receptor. A second segment is positioned downstream from the first segment (and in correct reading frame therewith), with the second segment comprising a DNA sequence encoding a heterologous G protein-coupled receptor.
Type:
Grant
Filed:
November 23, 2004
Date of Patent:
August 19, 2008
Assignee:
Duke University Office of Science and Technology
Inventors:
Klim King, Henrick G. Dohlman, Marc G. Caron, Robert J. Lefkowitz
Abstract: Genes whose expression is correlated with and determinant of an atherosclerotic phenotype are provided. Genes whose expression is correlated with and determinant of an atherosclerotic susceptibility are also provided. Also provided are methods of using the subject atherosclerotic determinant genes or the atherosclerotic susceptibility genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using at least one parameter that is not expression level and is preferably determined using a binary prediction tree analysis.
Type:
Application
Filed:
August 4, 2005
Publication date:
June 29, 2006
Applicant:
Duke University Office of Science and Technology
Inventors:
Mike West, Joseph Nevins, Pascal Goldschmidt, David Seo
Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
Type:
Application
Filed:
January 11, 2001
Publication date:
September 12, 2002
Applicant:
DUKE UNIVERSITY Office of Science and Technology
Inventors:
Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman